Back to Search Start Over

[Nucleic Acid-based Immuno-prophylaxis and -therapies against Tropical Diseases].

Authors :
Ishii KJ
Source :
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [Yakugaku Zasshi] 2022; Vol. 142 (7), pp. 709-713.
Publication Year :
2022

Abstract

The number of clinical trials investigating the use of nucleic acid drugs, including DNA/RNA-based vaccines, immunostimulatory/modulatory DNA/RNA and cyclic dinucleotides, for immuno-prophylaxis and -therapy has been increasing exponentially in recent years. These new drugs have revealed their therapeutic potential not only as vaccines or adjuvant therapies, but also as monotherapies for use in immuno-therapy of cancer and allergic disease. I will present an overview of their current R&D taking place in this field, then describe our recent progress, particularly regarding CpG oligodeoxynucleotides (ODNs), such as K3, K3-SPG, and D35 as either vaccine adjuvants or mono-immunotherapeutic agents for tropical diseases including malaria and leishmaniasis.

Details

Language :
Japanese
ISSN :
1347-5231
Volume :
142
Issue :
7
Database :
MEDLINE
Journal :
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Publication Type :
Academic Journal
Accession number :
35781498
Full Text :
https://doi.org/10.1248/yakushi.21-00210-5